An interventional study of HIV team implementation in HIV Infection, HIV and Stigma, sponsored by Casper Rokx. Recruiting at 28 sites in 10 countries. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-12.
Sponsored by Casper Rokx · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 86 studies in HIV Infections with a site in Netherlands — 6 open to participants now, 10 under way, 2 of them phase 3. HIV Infections · Netherlands.
Among the 86 studies in HIV Infections with a site in Netherlands, this one has the largest planned enrollment of the 74 interventional ones that give a count, is one of 2 that started in 2025, is one of 3 with no phase, and was the 84th registered.
4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.
Browse HIV Infections studies →6 of the 86 studies in HIV Infections with a site in Netherlands are open now. Recruiting first, the newest first:
ViiV Healthcare · Sites in Netherlands
Ages 18–55 · Healthy volunteers
Prof. Jan Prins · Sites in Netherlands
Ages 18+
Erasmus Medical Center · Sites in Netherlands
Ages 18+
Radboud University Medical Center · Sites in Netherlands, Belgium, Germany and 4 more countries
Ages 18+ · Women only
Erasmus Medical Center · Sites in Netherlands
Ages 18+
A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →
Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
86 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 17 · Phase 3 31 · Phase 4 15
First in 2000; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 5,200 is above the median of 80 across 3,492 interventional studies indexed under HIV Infections.
Median enrollment 206 across the 74 interventional studies, 330 across the 10 observational. Of the 67 that completed or were terminated, 28 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
45 of 86 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Casper Rokx as lead sponsor.
Casper Rokx has 1 study filed under HIV Infections — fewer than ten, so there is no comparison to draw.
3 of the studies in HIV Infections with a site in Netherlands that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT00825929Radboud University Medical CenterPharmacokinetics of Antiretroviral Agents in HIV-infected Pregnant Women. | 2026-12 |
| NCT04888754Erasmus Medical CenterA Prospective Cohort for ex Vivo Cure Studies With Chronic HIV Infected Patients in the Netherlands | 2027-01 |
| NCT07053384ViiV HealthcareA Study to Investigate the Use of VH3810109 With or Without Fostemsavir (FTR) to Reduce the Size and Activity of the Viral Reservoir in People Living With HIV | 2027-01-22 |
Add all 3 to your calendar (.ics) → With an account.
Among the 86 studies in HIV Infections with a site in Netherlands, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The #aware.hiv Europe study is a real-world, multicenter, stepped-wedge cluster randomized, effectiveness-implementation trial designed to evaluate whether the introduction of dedicated HIV teams in hospitals can improve HIV testing rates among patients presenting with HIV indicator conditions across ten European countries.
Study Design:
The study employs a stepped-wedge design, whereby clusters of hospitals transition sequentially from a control phase (routine care) to an intervention phase. All patient data are collected retrospectively from routine care, while prospective data are gathered at the healthcare professional level. The project spans four years and involves hospitals from the Netherlands, Belgium, United Kingdom, Germany, Spain, France, Italy, Romania, Poland, and Ukraine. This design allows for comparison of HIV testing rates and related outcomes before and after the implementation across different settings and time points.
Intervention:
The core intervention involves the establishment of hospital-based HIV teams. Each team is led by an HIV specialist and supported by nurses and data collectors. Their responsibilities include:
Identification and Surveillance: Screening routine electronic health records for HIV indicator conditions using predefined ICD-10 codes and verifying cases that warrant HIV testing.
Audit \& Feedback: Providing targeted recommendations to treating physicians when an HIV test is indicated but has not been performed, thereby prompting action.
Education \& Training: Delivering training sessions to healthcare professionals to improve their knowledge and attitudes towards HIV testing, prevention, and care.
Enabling Environment: Implementing digital solutions and other support mechanisms to streamline testing processes, reduce stigma, and enhance overall guideline adherence.
Linkage to prevention: Improving linkage to the locally available preventive services.
The intervention is intended to integrate seamlessly into routine hospital care, thereby reinforcing existing guidelines while addressing the current diagnostic testing gap.
Endpoints and Outcome Measures:
Primary Endpoint:
The change in HIV testing rate among patients diagnosed with HIV indicator conditions before and after the implementation of HIV teams.
Key Secondary Endpoints:
The change in the incidence of new HIV diagnoses among patients with HIV indicator conditions.
Variations in HIV testing rates across different countries, medical specialties, and types of indicator conditions, as well as over time.
Assessment of the cascade of HIV diagnosis, including the proportion of patients identified with an indicator condition, the offer and acceptance of HIV testing, and documented reasons for non-testing.
Evaluation of the cascade of HIV care and prevention, including linkage to HIV care, achievement of viral suppression, and referral and uptake of preventive services.
Changes in healthcare professionals' knowledge, attitudes, and levels of stigma towards HIV.
Implementation outcomes such as fidelity of HIV team activities, resource utilization, cost-effectiveness, and sustainability of the intervention.
Analysis of contextual factors, barriers, and facilitators impacting the implementation process, using established frameworks like CFIR and RE-AIM.
Impact:
By introducing HIV teams and systematically monitoring their effect on HIV testing practices, the study aims to enhance early HIV diagnosis and improve patient outcomes. The findings will contribute to evidence-based guidelines and may promote the adoption of similar interventions across European healthcare settings, ultimately reducing HIV-associated morbidity, mortality, and transmission rates.
This project not only addresses a critical diagnostic gap in HIV care but also provides valuable insights into the effective implementation of complex interventions in routine clinical practice.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Since this study involves screening individuals presenting to a specific hospital through a hospital-wide intervention, the inclusion and exclusion criteria are established at the hospital level.
Inclusion Criteria:
Exclusion Criteria:
Any hospital that does not meet the inclusion criteria will be excluded from participation. We will not use data of patients who have objected against the use of their data for research.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A local hiv team will be implemented in a certain hospital. This will result in different activities, with a focus on: * audit and feedback (reminding health care professionals to test for hiv) * stigma reduction (raising awareness on existing hiv stigma towards hiv) * education (increasing knowledge on hiv among health care professionals) * linkage to prevention and care (improving pathways for hiv care and prevention)
Behavioral: HIV team implementation
A local hiv team will be implemented in a certain hospital. This will result in different activities, with a focus on: * audit and feedback (reminding health care professionals to test for hiv) * stigma reduction (raising awareness on existing hiv stigma towards hiv) * education (increasing knowledge on hiv among health care professionals) * linkage to prevention and care (improving pathways for hiv care and prevention)
HIV testing rate in patients with HIV indicator conditions
Proportion of patients diagnosed with an HIV indicator condition who receive an HIV test, compared between the control and implementation phases.
Time frame: Comparison between 1 year of implementation and a control phase lasting between 6 to 18 months, depending on the site's randomization in the stepped-wedge trial design.
HIV incidence in patients with HIV indicator conditions
Number of newly diagnosed HIV infections among patients with an HIV indicator condition, compared between the control and implementation phases.
Time frame: Comparison between 1 year of implementation and a control phase lasting between 6 to 18 months, depending on the site's randomization in the stepped-wedge trial design.
Subgroup analysis 1: HIV testing rate by country and region
Difference in HIV testing rate within and between countries, as well as between geographic regions (West: Netherlands, Belgium, UK, Germany; South: France, Italy, Spain; East: Poland, Romania, Ukraine), comparing the control and implementation phases.
Time frame: Comparison between 1 year of implementation and a control phase lasting between 6 to 18 months, depending on the site's randomization in the stepped-wedge trial design.
Subgroup analysis 2: HIV testing rate by HIV indicator condition
Difference in HIV testing rate across different HIV indicator conditions, comparing the control and implementation phases.
Time frame: Comparison between 1 year of implementation and a control phase lasting between 6 to 18 months, depending on the site's randomization in the stepped-wedge trial design.
Subgroup analysis 3: HIV testing rate by medical specialty
Difference in HIV testing rate across medical specialties, comparing the control and implementation phases.
Time frame: Comparison between 1 year of implementation and a control phase lasting between 6 to 18 months, depending on the site's randomization in the stepped-wedge trial design.
Subgroup analysis 4: HIV testing rate over time
Change in HIV testing rate over time, comparing the control and implementation phases.
Time frame: Comparison between 1 year of implementation and a control phase lasting between 6 to 18 months, depending on the site's randomization in the stepped-wedge trial design.
Cascade 1: The cascade of HIV diagnosis
Proportion of patients with a confirmed HIV indicator condition (focus population) who were offered an HIV test (reach) and who accepted testing (uptake), compared between the control and implementation phases.
Time frame: Comparison between 1 year of implementation and a control phase lasting between 6 to 18 months, depending on the site's randomization in the stepped-wedge trial design.
Cascade 1b: The cascade of HIV diagnosis - reasons for not testing for HIV
Qualitative analysis of documented reasons why patients with an HIV indicator condition did not receive an HIV test. Reasons will be classified according to predefined categories used in the study database: No reason registered (1) Patient was not seen again (2) Advice to the general practitioner or public health to test (3) No perceived indication or risk factors (4) Alternative diagnosis/explanation (5) No recommendation in local protocol (6) Patient refused (7) Shared decision-making not to test (8) Lack of time or opportunity (9) Planned but not performed (10) Already tested (confirmed) (11) Already tested (not confirmed or inadequate according to the SOP) (12) Palliative care or patient deceased during follow-up (13) Other (14)
Time frame: Comparison between 1 year of implementation and a control phase lasting between 6 to 18 months, depending on the site's randomization in the stepped-wedge trial design.
Cascade 1c: The cascade of HIV diagnosis - descriptions of existing consent procedures in different hospital sites
Qualitative description of the consent procedures in place for HIV testing across different hospital sites. This includes: The types of consent procedures in use, such as verbal or written consent. National or institutional guidelines or local standard procedures that shape consent practices. Data will be collected per site to document existing practices without assessing implementation or adherence.
Time frame: Description of consent procedures as documented during the 1-year implementation phase across different hospital sites.
Cascade 2: The cascade of HIV care
Proportion of patients with a confirmed HIV indicator condition who were newly diagnosed with HIV (focus population) and subsequently linked or re-linked to routine HIV care (reach), with viral suppression as an indicator of successful engagement in care (uptake), compared between the control and implementation phases.
Time frame: Comparison between 1 year of implementation and a control phase lasting between 6 to 18 months, depending on the site's randomization in the stepped-wedge trial design.
Cascade 3: The cascade of HIV prevention
Proportion of patients with a confirmed HIV indicator condition who met the eligibility criteria for HIV prevention (focus population), were appropriately referred to prevention services (reach), and engaged in prevention interventions (uptake), compared between the control and implementation phases.
Time frame: Comparison between 1 year of implementation and a control phase lasting between 6 to 18 months, depending on the site's randomization in the stepped-wedge trial design.
HIV stigma indicators among health care professionals
Descriptive assessment of self-reported HIV stigma among licensed healthcare professionals, including physicians, nurse practitioners, and physician assistants, before and after implementation. Stigma will be measured using a validated questionnaire developed by the Health Policy Project and USAID, and adapted from the ECDC survey published in Annex 1 of the report: "HIV stigma in the healthcare setting. Monitoring implementation of the Dublin Declaration on partnership to fight HIV/AIDS in Europe and Central Asia 2024." The survey includes self-reported responses on multiple dimensions of HIV stigma, expressed as percentages of participants reporting: 1. Fear of HIV infection 2. Institutional facilitators and barriers 3. Negative attitudes towards people with HIV 4. Observed stigma in clinical settings. This is a descriptive outcome measure, reporting the proportion of participants endorsing each stigma-related item before and after the intervention.
Time frame: Assessed at baseline (before implementation) and at 12 months (after 1 year of implementation).
Implementation science 1: Assessment of key barriers and facilitators over time (CFIR)
Description: Descriptive assessment of perceived barriers and facilitators to implementing and sustaining the HIV team intervention in hospital settings. Barriers and facilitators will be assessed based on a structured survey, capturing key constructs from the Consolidated Framework for Implementation Research (CFIR): Intervention characteristics, Outer setting, Inner setting, Characteristics of individuals and the Implementation process. Survey items will be derived from a systematic review of barriers and facilitators to HIV indicator condition-based testing. The review will be published separately. Data will be collected via an online survey in Castor, administered to the HIV team lead at each participating site
Time frame: Every 3 months during the implementation phase (first year). Every 6 months during the continuation phase (up to 3 years post-implementation).
Implementation science 2: Reach: Proportion of patients benefiting from HIV team-supported testing
Proportion of patients with HIV indicator conditions who received an HIV test with direct (= feedback) or indirect (= other implementation strategies) involvement of the HIV team, stratified by: * Country, hospital, and specialty to assess variation in reach * Equity analysis: evaluating differences in testing uptake by age and sex
Time frame: Measured during the implementation phase (1st year) and continuation phase (2nd year), compared to the control phase (6-18 months before implementation).
Implementation science 3a: Effectiveness: Impact on HIV diagnosis rate
Proportion of individuals who test HIV-positive among: All individuals tested for HIV (primary analysis). All individuals identified with an HIV indicator condition (secondary analysis).
Time frame: Measured during the implementation phase (1st year) and continuation phase (2nd year), compared to the control phase (6-18 months before implementation).
Implementation science 3b: Effectiveness: Impact on disease stage at presentation
Assessment of the impact of the HIV indicator condition-based testing approach on CD4 count at HIV diagnosis, measured as a continuous variable to assess shifts in stage at presentation. Primary analysis: Mean CD4 count at HIV diagnosis in the intervention phase vs. control phase (continuous variable). Secondary analysis: Distribution of CD4 counts at diagnosis (percentiles and quartiles) to evaluate changes in the proportion of late-stage diagnoses. Proportion of patients diagnosed with advanced HIV (CD4 \<200 cells/µL) in both phases. Proportion of patients diagnosed with late-stage HIV (CD4 \<350 cells/µL) in both phases. Proportion of patients diagnosed at higher CD4 thresholds (e.g., \>500 cells/µL) to assess shifts towards earlier diagnosis.
Time frame: Measured during the implementation phase (1st year) and continuation phase (2nd year), compared to the control phase (6-18 months before implementation).
Implementation science 4a: Adoption of HIV Indicator Condition-based testing
Hospital adoption rate (%): Proportion of participating hospitals that have adopted all core components of HIV indicator condition-based testing. as well as: Degree of adoption across the hospital (%): Proportion of hospital departments (inpatients, outpatients, SEH, IC) that are included in the surveillance of HIV indicator condition-based testing.
Time frame: Measured during the implementation phase (1st year) and continuation phase (2nd year), compared to the control phase (6-18 months before implementation).
Implementation science 5a: Implementation - Fidelity to the implementation strategies
This outcome assesses the degree to which the #aware.hiv Europe implementation strategies were delivered as intended across participating hospitals. Percentage of flagged potential HIV indicator conditions that were assessed by the HIV team (surveillance) Percentage of untested indicator conditions for which HIV testing advice was provided to physicians (feedback) Number of teaching sessions delivered compared to the intended frequency, with a minimum of one session every three months in the implementation phase (teaching). Number of stigma-reducing events organized, with a minimum requirement of one event in the implementation phase (stigma).
Time frame: Measured during the implementation phase (1st year) and continuation phase (2nd year)
Implementation science 5b: Implementation - Adaptation of the implementation strategies
This outcome assesses the extent to which the #aware.hiv Europe implementation strategies were adapted to fit the local context while maintaining core components across participating hospitals. The number and type of modifications made to the implementation strategy at the hospital level will be assessed using qualitative data collected via a structured questionnaire. Responses will be categorized according to the key components of the implementation strategy: * Audit and Feedback * Teaching and Education * Enabling Environment (including stigma reduction) * Linkage to Prevention
Time frame: This will be assessed every three months during the implementation phase, and every 6 months in the first year of the continuation phase..
Implementation science 5c: Implementation - Acceptability and appropriateness of the implementation strategies
This outcome assesses how acceptable and appropriate the #aware.hiv Europe implementation strategies are perceived by healthcare professionals authorised to request HIV tests, using questions embedded in the hospital-wide stigma questionnaire.
Time frame: As part of the stigma questionnaire before and after the implementation phase.
Cost-effectiveness
Cost-effectiveness will be estimated by calculating the budget impact and Quality-Adjusted Life Years (QALYs) saved to define an Incremental Cost-Effectiveness Ratio (ICER).
Time frame: The one-year implementation phase will be compared to the preceding control phase, and the continuation phase (second year) will be compared to both the implementation and control phases to assess cost-effectiveness.
Epidemiological impact
The epidemiological impact will be estimated by quantifying the number of earlier HIV diagnoses achieved through the intervention, and modelling the resulting reduction in the number of person-years spent living with undiagnosed HIV. In addition, the number of secondary HIV infections potentially averted due to earlier diagnosis and treatment initiation will be estimated. Estimate the reduction in average time from infection to diagnosis based on clinical data and literature. Calculate the total number of person-years with undiagnosed HIV prevented through earlier detection. Use published transmission rates for undiagnosed individuals to model the number of secondary infections averted. If available, incorporate local or national modelling tools (e.g., ECDC HIV Modelling Tool) to support these estimates.
Time frame: The one-year implementation phase will be compared to the control phase, and the continuation phase (second year) will be compared to both preceding phases.
Plan to share: No — While aggregated results may be published, the protocol does not support the sharing of individual-level data.
Started Oct 2025 (actual). Primary completion is estimated for Apr 2029, 42 months after the start.
Of 393 non-industry interventional studies with no phase under HIV Infections, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 45. This study's planned 42 months is above that.
Counting every sponsor, half of 402 studies reached it within 28 months; a quarter within 16 and three quarters within 45.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.